238 related articles for article (PubMed ID: 35964022)
21. Low expression of moonlight gene ALAD is correlated with poor prognosis in hepatocellular carcinoma.
Ye Q; Yang X; Zheng S; Mao X; Shao Y; Xuan Z; Huang P
Gene; 2022 May; 825():146437. PubMed ID: 35318110
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Value of Cancer-Associated Fibroblast-Related Gene Signatures in Hepatocellular Carcinoma.
Dong W; Xie Y; Huang H
Front Endocrinol (Lausanne); 2022; 13():884777. PubMed ID: 35733776
[TBL] [Abstract][Full Text] [Related]
23. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
[TBL] [Abstract][Full Text] [Related]
24. Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes.
Gu X; Guan J; Xu J; Zheng Q; Chen C; Yang Q; Huang C; Wang G; Zhou H; Chen Z; Zhu H
J Transl Med; 2021 Jan; 19(1):26. PubMed ID: 33407546
[TBL] [Abstract][Full Text] [Related]
25. Pan-cancer analysis of LRRC59 with a focus on prognostic and immunological roles in hepatocellular carcinoma.
Pan B; Cheng J; Tan W; Wu X; Fan Q; Fan L; Jiang M; Yu R; Cheng X; Deng Y
Aging (Albany NY); 2024 May; 16(9):8171-8197. PubMed ID: 38738999
[TBL] [Abstract][Full Text] [Related]
26. The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma.
Wu SY; Xie ZY; Yan LY; Liu XF; Zhang Y; Wang DA; Dong J; Sun HT
BMC Immunol; 2022 Jun; 23(1):28. PubMed ID: 35659256
[TBL] [Abstract][Full Text] [Related]
27. Development and validation of LRP1B mutation-associated prognostic model for hepatocellular carcinoma.
Xu J; Shen X; Zhang B; Su R; Cui M; Yan L; Cao Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34386813
[TBL] [Abstract][Full Text] [Related]
28. Construction and validation of an IRF4 risk score to predict prognosis and response to immunotherapy in hepatocellular carcinoma.
Yuan J; Liu Z; Wu Z; Yang J; Yang J
Int Immunopharmacol; 2022 Dec; 113(Pt A):109411. PubMed ID: 36461603
[TBL] [Abstract][Full Text] [Related]
29. Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy.
Abaza T; El-Aziz MKA; Daniel KA; Karousi P; Papatsirou M; Fahmy SA; Hamdy NM; Kontos CK; Youness RA
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003674
[TBL] [Abstract][Full Text] [Related]
30. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.
Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D
Front Immunol; 2022; 13():862527. PubMed ID: 35493471
[TBL] [Abstract][Full Text] [Related]
31. Elevated
Cheng Q; Wang W; Liu J; Lv Z; Ji W; Yu J; Zhang W; Yang Y
Front Immunol; 2023; 14():1173848. PubMed ID: 37207207
[TBL] [Abstract][Full Text] [Related]
32. Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma.
Liu Z; Liu L; Guo C; Yu S; Meng L; Zhou X; Han X
Int Immunopharmacol; 2021 Dec; 101(Pt B):108340. PubMed ID: 34789428
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma.
Chen J; Gingold JA; Su X
Trends Mol Med; 2019 Nov; 25(11):1010-1023. PubMed ID: 31353124
[TBL] [Abstract][Full Text] [Related]
34. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma.
Dai Y; Qiang W; Lin K; Gui Y; Lan X; Wang D
Cancer Immunol Immunother; 2021 Apr; 70(4):967-979. PubMed ID: 33089373
[TBL] [Abstract][Full Text] [Related]
35. SAAL1, a novel oncogene, is associated with prognosis and immunotherapy in multiple types of cancer.
Yang W; Han B; Chen Y; Geng F
Aging (Albany NY); 2022 Aug; 14(15):6316-6337. PubMed ID: 35963646
[TBL] [Abstract][Full Text] [Related]
36. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
37. Molecular subtypes based on Wnt-signaling gene expression predict prognosis and tumor microenvironment in hepatocellular carcinoma.
Xu W; Nie C; Lv H; Chen B; Wang J; Wang S; Zhao J; He Y; Chen X
Front Immunol; 2022; 13():1010554. PubMed ID: 36275697
[TBL] [Abstract][Full Text] [Related]
38. NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma.
Ning YM; Lin K; Liu XP; Ding Y; Jiang X; Zhang Z; Xuan YT; Dong L; Liu L; Wang F; Zhao Q; Wang HZ; Fang J
BMC Gastroenterol; 2022 Aug; 22(1):392. PubMed ID: 35987606
[TBL] [Abstract][Full Text] [Related]
39. High ADAM8 expression is associated with poor prognosis in patients with hepatocellular carcinoma.
Zhang Y; Tan YF; Jiang C; Zhang K; Zha TZ; Zhang M
Pathol Oncol Res; 2013 Jan; 19(1):79-88. PubMed ID: 22965687
[TBL] [Abstract][Full Text] [Related]
40. Prognostic stratification based on m
Liu P; Zhu Z; Ma J; Wei L; Han Y; Shen E; Tan X; Chen Y; Cai C; Guo C; Peng Y; Gao Y; Liu Y; Huang Q; Gao L; Li Y; Jiang Z; Wu W; Liu Y; Zeng S; Li W; Feng Z; Shen H
Front Immunol; 2022; 13():951529. PubMed ID: 36159831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
